Table 1. Clinical data and tubular scoring of PARs in diabetic nephropathy patients and non-diabetic control subjects.
| Patient type | Age/Genderat biopsy | HbA1C (%) | Serumcreatinine(µmol/L) | Urine proteinexcretion (g)per 24 h | Immunohistochemical staining score* | |||
| PAR-1 | PAR-2 | PAR-3 | PAR-4 | |||||
| Non-diabetic control group | ||||||||
| 1 | 53/F | 7.9 | 97 | <0.03 | 0 | 2 | 1 | 0 |
| 2 | 47/M | N/A | 70 | <0.03 | 0 | 1 | 0 | 1 |
| 3 | 78/F | N/A | 71 | N/A | 1 | 1 | 0 | 1 |
| 4 | 53/M | N/A | 114 | 100 mg/dL | 0 | 1 | 1 | 0 |
| 5 | 74/M | N/A | 87 | <0.03 | 1 | 1 | 1 | 1 |
| Diabetic nephropathy group | ||||||||
| 6 | 50/M | 9.3 | 227 | 1.97 | 0 | 4 | 1 | 4 |
| 7 | 47/M | 6.6 | 844 | 4.92 | 1 | 2 | 1 | 3 |
| 8 | 65/M | 5.9 | 750 | 6.05 | 2 | 4 | 2 | 2 |
| 9 | 50/M | 7.9 | 215 | 11.30 | 1 | 3 | 1 | 2 |
| 10 | 65/F | 6.2 | 284 | 4.74 | 1 | 3 | 0 | 2 |
* quantified on a scoring system 0–5 in which 0 = no cortical staining; 1 = <10% cortical staining; 2 = 10–20% cortical staining; 3 = 20–40% cortical staining; 4 = 40–60% cortical staining; 5 = >60% cortical staining.